{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:45:34Z","timestamp":1785725134639,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573617"],"award-info":[{"award-number":["82573617"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L248050"],"award-info":[{"award-number":["L248050"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218580","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:19:46Z","timestamp":1778771986000},"page":"218580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["RAD21 drives tumor progression and confers anti-PD-1 resistance by reprogramming tumor-associated macrophages via upregulation of CSF1 signaling"],"prefix":"10.1016","volume":"657","author":[{"given":"Wenpeng","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianle","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0327-8852","authenticated-orcid":false,"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2026.218580_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-024-01640-8","article-title":"Global burden of cancer and associated risk factors in 204 countries and territories, 1980-2021: a systematic analysis for the GBD 2021","volume":"17","author":"Wu","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.canlet.2026.218580_bib2","doi-asserted-by":"crossref","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","article-title":"National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data","volume":"8","author":"Qi","year":"2023","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.canlet.2026.218580_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-031-97242-3_1","article-title":"Cancer Immunotherapy-An overview","volume":"129","author":"Kulkarni","year":"2025","journal-title":"Cancer Treat Res."},{"key":"10.1016\/j.canlet.2026.218580_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100907","article-title":"Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1\/PD-L1 blockade","volume":"66","author":"Pang","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"6","key":"10.1016\/j.canlet.2026.218580_bib5","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-Line immunotherapy for non-small-cell lung cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218580_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ccell.2023.03.016","article-title":"An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"issue":"10445","key":"10.1016\/j.canlet.2026.218580_bib7","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218580_bib8","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fcell.2020.00672","article-title":"Resistance mechanisms of Anti-PD1\/PDL1 therapy in solid tumors","volume":"8","author":"Lei","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"26","key":"10.1016\/j.canlet.2026.218580_bib9","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.canlet.2026.218580_bib10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2026.218580_bib11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cac2.12539","article-title":"Immunologic tumor microenvironment modulators for turning cold tumors hot","volume":"44","author":"Khosravi","year":"2024","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218580_bib12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2026.218580_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","article-title":"Targeting KRAS mutant cancers: from druggable therapy to drug resistance","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.canlet.2026.218580_bib14","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218580_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.788365","article-title":"Tumor associated macrophages: origin, recruitment, phenotypic diversity, and targeting","volume":"11","author":"Hourani","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2026.218580_bib16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metab."},{"issue":"11","key":"10.1016\/j.canlet.2026.218580_bib17","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/cac2.12345","article-title":"Tumor-associated macrophages in liver cancer: from mechanisms to therapy","volume":"42","author":"Cheng","year":"2022","journal-title":"Cancer Commun."},{"issue":"1","key":"10.1016\/j.canlet.2026.218580_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2115655","article-title":"CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment","volume":"11","author":"Lecoq","year":"2022","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.canlet.2026.218580_bib19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tcb.2004.09.016","article-title":"CSF-1 regulation of the wandering macrophage: complexity in action","volume":"14","author":"Pixley","year":"2004","journal-title":"Trends Cell Biol."},{"issue":"6687","key":"10.1016\/j.canlet.2026.218580_bib20","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1126\/science.adl4606","article-title":"Sister chromatid cohesion is mediated by individual cohesin complexes","volume":"383","author":"Ochs","year":"2024","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.canlet.2026.218580_bib21","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/j.cell.2024.04.014","article-title":"Vertebrate centromeres in mitosis are functionally bipartite structures stabilized by cohesin","volume":"187","author":"Sacristan","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2026.218580_bib22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13046-022-02321-5","article-title":"The multifaceted roles of cohesin in cancer","volume":"41","author":"Di Nardo","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.canlet.2026.218580_bib23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41568-020-0270-1","article-title":"Emerging themes in cohesin cancer biology","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218580_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218062","article-title":"RAD21-mediated epigenetic regulation promotes lung adenocarcinoma progression and sensitizes cancer cells to ERK-targeted therapy","volume":"634","author":"Xiao","year":"2025","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.canlet.2026.218580_bib25","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.celrep.2014.10.059","article-title":"Cohesin Rad21 mediates loss of heterozygosity and is upregulated via Wnt promoting transcriptional dysregulation in gastrointestinal tumors","volume":"9","author":"Xu","year":"2014","journal-title":"Cell Rep."},{"issue":"37","key":"10.1016\/j.canlet.2026.218580_bib26","doi-asserted-by":"crossref","first-page":"61777","DOI":"10.18632\/oncotarget.18693","article-title":"Polymorphisms in mitotic checkpoint-related genes can influence survival outcomes of early-stage non-small cell lung cancer","volume":"8","author":"Kang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218580_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115119","article-title":"Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: a pooled analysis in 935 patients","volume":"214","author":"Robert","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218580_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1475502","article-title":"Efficacy and safety of immune checkpoint inhibitors rechallenge in advanced solid tumors: a systematic review and meta-analysis","volume":"14","author":"Cao","year":"2024","journal-title":"Front. Oncol."},{"issue":"10","key":"10.1016\/j.canlet.2026.218580_bib29","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1158\/1078-0432.CCR-18-1942","article-title":"WNT\/beta-catenin pathway activation correlates with immune exclusion across human cancers","volume":"25","author":"Luke","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2026.218580_bib30","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 Mutations and PD-1 inhibitor resistance in KRAS-Mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov."},{"issue":"21","key":"10.1016\/j.canlet.2026.218580_bib31","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1158\/1078-0432.CCR-24-3399","article-title":"Amplification of Extrachromosomal MYC paralogs shapes immunosuppressive tumor microenvironment in small cell lung cancer","volume":"31","author":"Zhang","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.canlet.2026.218580_bib32","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159628","article-title":"RAD21 amplification epigenetically suppresses interferon signaling to promote immune evasion in ovarian cancer","volume":"132","author":"Deng","year":"2022","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.canlet.2026.218580_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s11658-022-00376-y","article-title":"LARRPM restricts lung adenocarcinoma progression and M2 macrophage polarization through epigenetically regulating LINC00240 and CSF1","volume":"27","author":"Li","year":"2022","journal-title":"Cell. Mol. Biol. Lett."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526003435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526003435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:22:19Z","timestamp":1785723739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526003435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"alternative-id":["S0304383526003435"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218580","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RAD21 drives tumor progression and confers anti-PD-1 resistance by reprogramming tumor-associated macrophages via upregulation of CSF1 signaling","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218580"}}